ECM
IMGN

Estabrook Capital Management’s Immunogen Inc IMGN Stock Holding History

Estabrook Capital Management’s Portfolio IMGN Stock Details IMGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-136
Closed -$1.61K – 471
2014
Q2 		$1.61K Buy
+136
New +$1.71K ﹤0.01% 437

Other funds holding IMGN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Estabrook Capital Management's IMGN Position: Q3 2014 in Review

Estabrook Capital Management sold out of Immunogen Inc (IMGN) in Q3 2014, closing a stake of 136 shares — an estimated $1.61K sold.

Estabrook Capital Management first reported a position in IMGN in Q2 2014 and held it in 1 quarter. The position peaked at $1.61K in Q2 2014. 141 funds tracked by Wall St. Rank hold IMGN as of Q3 2014.

  • Estabrook Capital Management reported no remaining Immunogen Inc position as of Q3 2014 after selling out during the quarter.
  • Estabrook Capital Management sold 136 Immunogen Inc shares in Q3 2014, an estimated $1.61K.
  • Estabrook Capital Management first reported a position in Immunogen Inc in Q2 2014 and held it in 1 quarter.
  • Estabrook Capital Management's Immunogen Inc position peaked at $1.61K in Q2 2014.
  • 141 funds tracked by Wall St. Rank held Immunogen Inc as of Q3 2014.

Based on Estabrook Capital Management's 13F filing for Q3 2014, filed 13 Nov 2014.